{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:33:50Z","timestamp":1764311630639,"version":"3.46.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To evaluate the efficacy of COVID-19 convalescent plasma (CCP) in preventing SARS-CoV-2 infection in hematopoietic stem cell transplantation (HSCT) recipients during the early post-transplant period, a single-center, randomized controlled trial was conducted between June 2023 and February 2024. Seventy-two participants were randomized 1:1 to receive CCP (200 mL on days +14, +28, +2 months, and +3 months post-transplant) or standard treatment. The primary outcome was COVID-19 infection within 28 days after the last infusion; secondary outcomes included severe infection, adverse events, and survival. The CCP and standard treatment group each included 36 patients. In the CCP group, 26 (72.2%, 26\/36) patients completed four cycles of plasma infusion and 33 (33\/36, 91.7%) patients received at least one infusion. The median time to infection was 95 days (IQR 81-106) in the CCP group and 74 days (IQR 48-110) in the standard group (p = 0.272). The 120-day cumulative COVID-19 incidence was 32.1% (95% CI, 14.5-46.1%) in the CCP group and 22.9% (95% CI, 7.6-35.6%) in the standard treatment group (p=0.459). Severe cases occurred in one patient per group, with no 30-day mortality. One-year overall survival (OS) was lower in the CCP group compared to the standard treatment group (73.1% [95% CI, 59.4-90.0%] vs. 91.7% [83.1-100%], p=0.044). At 90 days post-transplantation, the peripheral blood CD4\/CD8 ratio in patients of the CCP group was significantly lower than that in the standard treatment group (p = 0.008). Adverse events were observed in only 3 patients and were mild. CCP recipients had higher antibody levels, but differences were not significant. These findings indicate that CCP did not prevent COVID-19 infection and may have limited efficacy in early post-transplant patients.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical Trials<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      , identifier NCT05904067.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1626775","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:42Z","timestamp":1764311382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Yigeng","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","unstructured":"WHO COVID-19 dashboard"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101399","article-title":"COVID-19 and HSCT (Hematopoietic stem cell transplant)","volume":"35","author":"Strasfeld","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/bjh.18312","article-title":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant","volume":"198","author":"Murray","year":"2022","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2021006937","article-title":"Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity","volume":"6","author":"Einarsdottir","year":"2022","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41409-022-01666-x","article-title":"Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation","volume":"57","author":"Massoud","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.21147\/j.issn.1000-9604.2024.05.06","article-title":"Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"36","author":"Wang","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1324019","article-title":"Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort","volume":"14","author":"Gao","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1056\/NEJMoa2209502","article-title":"Convalescent plasma for covid-19-induced ARDS in mechanically ventilated patients","volume":"389","author":"Misset","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.21147\/j.issn.1000-9604.2025.03.10","article-title":"Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group","volume":"37","author":"Wen","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"B13","unstructured":"Guidance on maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19) and other viral haemorrhagic fevers\n          \n          \n          \n          2021"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2250647","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: A systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological Malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100408","article-title":"Novel microfluidic device for measurable residual disease detection in acute leukemia","volume":"4","author":"Cai","year":"2023","journal-title":"Innovation (Camb)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.26792","article-title":"The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases","volume":"98","author":"Cao","year":"2023","journal-title":"Am J Hematol"},{"key":"B18","unstructured":"The EBMT handbook: hematopoietic cell transplantation and cellular therapies\n          \n          \n            \n              Sureda A\n              CS\n            \n            \n              Greco\n              R\n            \n          \n          \n          2024"},{"key":"B19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3760\/cma.j.cn121090-20240817-00308","article-title":"Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management","volume":"45","author":"Liu","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105549","article-title":"A comparative cohort study of post-COVID-19 conditions based on physical examination records in China","volume":"112","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2483","DOI":"10.1002\/rmv.2483","article-title":"COVID-19 in hematopoietic stem-cell transplant recipients: A systematic review and meta-analysis of clinical characteristics and outcomes","volume":"33","author":"Randi","year":"2023","journal-title":"Rev Med Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae038","article-title":"Characteristics of coronavirus disease in allogeneic hematopoietic stem cell transplantation during the omicron wave: A single-center study","volume":"11","author":"Zhu","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood.2021012248","article-title":"COVID-19 convalescent plasma","volume":"140","author":"Tobian","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid Malignancy and COVID-19: a longitudinal cohort and propensity score analysis","volume":"36","author":"Hueso","year":"2022","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1080\/10428194.2021.1966782","article-title":"COVID-19 among patients with hematological Malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome","volume":"62","author":"Levy","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102871","article-title":"Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma","volume":"59","author":"Karatas","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e20200372","DOI":"10.1590\/0037-8682-0372-2020","article-title":"Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports","volume":"53","author":"Wei","year":"2020","journal-title":"Rev Soc Bras Med Trop"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: A randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"Begin","year":"2021","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01724-2021","article-title":"Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma","volume":"59","author":"Devos","year":"2022","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1093\/cid\/ciac372","article-title":"Transfusing convalescent plasma as post-exposure prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) infection: A double-blinded, phase 2 randomized, controlled trial","volume":"76","author":"Shoham","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.12.20169359","article-title":"Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience","author":"Joyner","year":"2020","journal-title":"medRxiv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e13107","DOI":"10.1111\/irv.13107","article-title":"Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022","volume":"17","author":"Shah","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125030","article-title":"Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry","volume":"14","author":"Busca","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"337 e1","DOI":"10.1016\/j.jtct.2022.03.010","article-title":"High mortality of COVID-19 early after allogeneic stem cell transplantation: A retrospective multicenter analysis on behalf of the german cooperative transplant study group","volume":"28","author":"Schaffrath","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:45Z","timestamp":1764311385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1626775"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1626775","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1626775"}}